Nebivolol Teva (Nebivolol Hydrochloride)

• Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management.
• Hypertension: lowers systemic blood pressure by reducing cardiac output and promoting nitric‑oxide mediated vasodilation.
• Heart failure: improves left‑ventricular ejection fraction and reduces the risk of hospitalization in patients with reduced‑ejection‑fraction heart failure.

• Nebivolol Hydrochloride selectively antagonises β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility. Concurrently, it stimulates endothelial nitric‑oxide synthase, leading to nitric‑oxide release and vasodilation of peripheral vessels, which together lower arterial pressure and improve cardiac output in heart‑failure states.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially on standing.
• Fatigue or general tiredness.
• Nasal congestion or rhinorrhoea.
• Nausea or mild gastrointestinal upset.
• Tinnitus or ringing in the ears.

Serious or Rare Side Effects

• Severe bradycardia or heart block.
• Marked hypotension leading to syncope.
• Bronchospasm in patients with reactive airway disease.
• Allergic reactions such as rash, angioedema, or anaphylaxis.
• Hepatic enzyme elevation or liver injury.
• Worsening heart failure or pulmonary edema.

• Before initiating Nebivolol, clinicians should assess patient‑specific factors and monitor for potential complications.
• Monitor blood pressure: ensure adequate control without excessive hypotension.
• Assess cardiac function: evaluate heart rate and rhythm regularly.
• Use caution in asthma or COPD: β‑blockade may precipitate bronchospasm.
• Review concomitant beta‑blockers: avoid additive cardiac depression.
• Adjust in renal impairment: dose may need modification based on renal function.
• Store at room temperature: keep in the original pack, protect from moisture.

Nebivolol can interact with several drug classes; understanding the severity helps guide clinical decisions.

Major Interactions (Avoid)

• Non‑selective beta‑blockers: risk of excessive β‑blockade.
• Calcium‑channel blockers (verapamil, diltiazem): may cause profound bradycardia.
• Other antihypertensives: additive hypotensive effect.
• Strong CYP2D6 inhibitors (paroxetine, fluoxetine): increase nebivolol plasma levels.
• Insulin or oral hypoglycemics: may mask hypoglycaemia symptoms.

Moderate Interactions (Monitor Closely)

• Diuretics: monitor electrolytes and blood pressure.
• NSAIDs: may reduce antihypertensive efficacy.
• Certain antidepressants (sertraline): observe for heart‑rate changes.